-
EP3641782
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3641782
| EP3641782 - COMBINATION THERAPIES COMPRISING TARGETED THERAPEUTICS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 19.04.2024 Database last updated on 03.09.2024 | |
| Former | Request for examination was made Status updated on 27.03.2020 | ||
| Former | The international publication has been made Status updated on 31.12.2018 | Most recent event Tooltip | 19.04.2024 | Application deemed to be withdrawn | published on 22.05.2024 [2024/21] | Applicant(s) | For all designated states Madrigal Pharmaceuticals, Inc. Four Tower Bridge 200 Barr Harbor Drive, Suite 400 West Conshohocken, Pennsylvania 19428 / US | [2020/18] | Inventor(s) | 01 /
YING, Weiwen 15 Potter Pond Lexington, Massachusetts 02421 / US | 02 /
CHIMMANAMADA, Dinesh U. 78 Summer Street Apt. 4 Arlington, Massachusetts 02474 / US | 03 /
PROIA, David 30 Silver Lake Avenue Newton, Massachusetts 02458 / US | [2020/18] | Representative(s) | Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE | [N/P] |
| Former [2020/18] | Adam, Holger, et al Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE | Application number, filing date | 18821244.3 | 19.06.2018 | [2020/18] | WO2018US38172 | Priority number, date | US201762522306P | 20.06.2017 Original published format: US 201762522306 P | [2020/18] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2018236791 | Date: | 27.12.2018 | Language: | EN | [2018/52] | Type: | A1 Application with search report | No.: | EP3641782 | Date: | 29.04.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 27.12.2018 takes the place of the publication of the European patent application. | [2020/18] | Search report(s) | International search report - published on: | US | 27.12.2018 | (Supplementary) European search report - dispatched on: | EP | 18.02.2021 | Classification | IPC: | A61K31/502, A61K31/5025, A61P35/00, A61K45/06 | [2021/12] | CPC: |
A61K45/06 (EP,IL,KR);
A61K31/5025 (EP,IL,KR,US);
A61K31/4375 (IL,US);
A61K31/502 (EP,IL,KR,US);
A61K9/0019 (IL,US);
A61K9/0053 (IL,US);
| C-Set: |
A61K31/5025, A61K2300/00 (EP);
A61K31/502, A61K2300/00 (EP) |
| Former IPC [2020/18] | A61K31/70, A61K31/167, A61K31/4184 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/18] | Title | German: | KOMBINATIONSTHERAPIEN MIT GEZIELTEN THERAPEUTIKA | [2020/18] | English: | COMBINATION THERAPIES COMPRISING TARGETED THERAPEUTICS | [2020/18] | French: | THÉRAPIES COMBINÉES COMPRENANT DES THÉRAPEUTIQUES CIBLÉES | [2020/18] | Entry into regional phase | 20.12.2019 | National basic fee paid | 20.12.2019 | Search fee paid | 20.12.2019 | Designation fee(s) paid | 20.12.2019 | Examination fee paid | Examination procedure | 20.12.2019 | Examination requested [2020/18] | 10.12.2021 | Amendment by applicant (claims and/or description) | 03.01.2024 | Application deemed to be withdrawn, date of legal effect [2024/21] | 23.01.2024 | Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time [2024/21] | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report | 10.12.2021 | Request for further processing filed | 10.12.2021 | Full payment received (date of receipt of payment) Request granted | 21.12.2021 | Decision despatched | Fees paid | Renewal fee | 29.06.2020 | Renewal fee patent year 03 | 28.06.2021 | Renewal fee patent year 04 | 27.06.2022 | Renewal fee patent year 05 | Penalty fee | Additional fee for renewal fee | 30.06.2023 | 06 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [I]WO2013158644 (SYNTA PHARMACEUTICALS CORP [US]) [I] 1-15 * claims 1-4, 8-11 ** example 15 * | International search | US2017128589 [y] (LIM HYUNG KYU [KR], et al) [y] 1-16; | [yY] - Dréan, A. et al., "PARP inhibitor combination therapy.", Crit Rev Oncol Hematol., (20161031), vol. 108, doi:10.1016/j.critrevonc.2016.10.010, pages 73 - 85, XP029827859 [y] 1-16 DOI: http://dx.doi.org/10.1016/j.critrevonc.2016.10.010 | [yY] - Ricks, T.K. et al., "Study title: AZD2281: Oral fertility and early embryonic study in the male rat. Study no. : 1558GR", Study, Alderiey Park, Macclesfield, SK10 4TG, England, (20141202), pages 1 - 68, XP009518604 [y] 5 | [yY] - Feng, Y. et al., "Talazoparib (BMN-673) as single agent and in combination with Temozolomide or PI3K pathway inhibitors in small cell lung cancer and gastric cancer models models", 26th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics, Barcelona, Spain, (20140018), XP055539658 [y] 10 |